BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 17520094)

  • 1. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
    Horvath EM; Szabó C
    Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications.
    Nguewa PA; Fuertes MA; Valladares B; Alonso C; Pérez JM
    Prog Biophys Mol Biol; 2005 May; 88(1):143-72. PubMed ID: 15561303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PARP inhibitors for cancer therapy].
    Saito H; Miki Y
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
    Ratnam K; Low JA
    Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
    Jagtap P; Szabó C
    Nat Rev Drug Discov; 2005 May; 4(5):421-40. PubMed ID: 15864271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Poly(ADP-ribose) polymerase (PARP): physiological and pathological roles].
    Makogon NV; Aleksieieva IM
    Fiziol Zh (1994); 2012; 58(3):95-112. PubMed ID: 22946318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C; Low JA
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications.
    Sodhi RK; Singh N; Jaggi AS
    Vascul Pharmacol; 2010; 53(3-4):77-87. PubMed ID: 20633699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
    Virág L; Szabó C
    Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
    Papeo G; Forte B; Orsini P; Perrera C; Posteri H; Scolaro A; Montagnoli A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1377-400. PubMed ID: 19743897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP as a Drug Target for the Therapy of Diabetic Cardiovascular Dysfunction.
    Szabo C
    Drug News Perspect; 2002 May; 15(4):197-205. PubMed ID: 12677203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors.
    Putt KS; Hergenrother PJ
    Anal Biochem; 2004 Mar; 326(1):78-86. PubMed ID: 14769338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose) polymerase].
    Boulu RG; Mesenge C; Charriaut-Marlangue C; Verrecchia C; Plotkine M
    Bull Acad Natl Med; 2001; 185(3):555-63; discussion 564-5. PubMed ID: 11501263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
    Masutani M; Nakagama H; Sugimura T
    Cell Mol Life Sci; 2005 Apr; 62(7-8):769-83. PubMed ID: 15868402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors.
    Eltze T; Boer R; Wagner T; Weinbrenner S; McDonald MC; Thiemermann C; Bürkle A; Klein T
    Mol Pharmacol; 2008 Dec; 74(6):1587-98. PubMed ID: 18809672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
    Yap TA; Sandhu SK; Carden CP; de Bono JS
    CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP-ribose) polymerase inhibitors.
    Southan GJ; Szabó C
    Curr Med Chem; 2003 Feb; 10(4):321-40. PubMed ID: 12570705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward specific functions of poly(ADP-ribose) polymerase-2.
    Yélamos J; Schreiber V; Dantzer F
    Trends Mol Med; 2008 Apr; 14(4):169-78. PubMed ID: 18353725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoprotective effect of gallotannin in oxidatively stressed HaCaT keratinocytes: the role of poly(ADP-ribose) metabolism.
    Bakondi E; Bai P; Erdélyi K; Szabó C; Gergely P; Virág L
    Exp Dermatol; 2004 Mar; 13(3):170-8. PubMed ID: 14987257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.